[HTML][HTML] Galectin-1 pulls the strings on VEGFR2
P Stanley - Cell, 2014 - cell.com
Cell, 2014•cell.com
Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis
but development of resistance in patients is common. In this issue of Cell, Croci et al. identify
a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF
receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.
but development of resistance in patients is common. In this issue of Cell, Croci et al. identify
a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF
receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.
Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.
cell.com